重大公告
OBI Received a Civil Complaint from Taiwan Shilin District Court
Parties to the legal matter: Plaintiff: Securities and Futures Investors Protection Center (SFIPC) Defendant: OBI Pharma, Inc. and Dr. Michael N. Chang (Chairman) Name of …
Clarification on the news article by China Times
Date of occurrence: July 12, 2017 Company name: OBI Pharma, Inc. Relationship to the Company (please enter ”head office” or ”affiliated company”): N/A Reciprocal shareholding …
Clarification on the news article by Commercial Times
Date of occurrence: June 29, 2017 Company name: OBI Pharma, Inc. Relationship to the Company (please enter ”head office” or ”affiliated company”): N/A Reciprocal shareholding …
Important Resolutions of AGM 2017
Date of the meeting: June 28, 2017 Resolution #1: The 2016 earning distribution and expense appropriation was recognized. Resolution #2: Amended items—None Resolution #3: The …
Supplemental information on the approved application of Phase III clinical trial of OBI-822, the novel breast cancer drug, in China, US, and the EU
Date of occurrence: June 11, 2017 Company name: OBI Pharma, Inc. Relationship to the Company (please enter ”head office” or ”affiliated company”): N/A Reciprocal shareholding …